A Phase 2 interventional study of Zilovertamab vedotin in Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer and NSCLC, sponsored by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Terminated at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-10.
Sponsored by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc — 3 open to participants now, 3 under way, 3 of them phase 3. Triple Negative Breast Neoplasms · Merck & Co., Inc.
Among the 17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc, this one is the 11th largest by enrollment, is the only one that started in 2020, is one of 5 in phase 2, and was the 11th registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →3 of the 17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 38 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 32 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
By country, each count listing its studies:
Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 462 across the 17 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), one of the names counted as Merck & Co., Inc. Under that name alone:
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 2 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC human epidermal growth factor receptor 2 (HER2)-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and platinum-resistant ovarian cancer. The study will evaluate a null hypothesis that the objective response rate (ORR) is ≤5% against the alternative hypothesis that it is ≥20%.
Participants enrolled prior to Amendment 3 will receive zilovertamab vedotin at 2.5 mg/kg given intravenously on Day 1 of repeated 21-day cycles. Participants enrolled after Amendment 3 will receive zilovertamab vedotin at 1.75 mg/kg given intravenously on Day 1 and Day 8 of repeated 21-day cycles. Treatment will continue until progressive disease or discontinuation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive intravenous (IV) zilovertamab vedotin 2.5 mg/kg on Day 1 of each repeated 21-day cycle (Q1/3W) or 1.75 mg/kg on Day 1 and Day 8 of each 21-day cycle (Q2/3W). Treatment will continue until progressive disease or discontinuation
Drug: Zilovertamab vedotin
Intravenous infusion
Also known as: MK-2140, VLS-101
Objective Response Rate (ORR)- Blinded Independent Central Review (BICR)
The percentage of participants who achieved a Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: a ≥30% decrease in the sum of diameters \[SOD\] of target lesions) using per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 by BICR was reported.
Time frame: Up to ~18 months
ORR- Investigator Assessed
The percentage of participants who achieved a CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters \[SOD\] of target lesions) per RECIST, Version 1.1 by investigator was reported.
Time frame: Up to ~18 months
Time to Response (TTR)- BICR
TTR, defined as the time from the start of study treatment to the first documentation of objective tumor response per RECIST, Version 1.1 by BICR was reported.
Time frame: Up to ~30 months
Duration of Response (DOR)- BICR
DOR, defined as the interval from the first documentation of objective tumor response to the earlier of the first documentation of disease progression or death from any cause per RECIST, Version 1.1 by BICR was reported.
Time frame: Up to ~30 months
Progression-free Survival (PFS)- BICR
PFS, defined as the interval from the start of study treatment to the earlier of the first documentation of disease progression or death from any cause per RECIST, Version 1.1 by BICR was reported.
Time frame: Up to ~30 months
Time to Treatment Failure (TTF)- BICR
TTF, defined as the time from the start of study treatment to the earliest of the first documentation of disease progression, the permanent cessation of study drug due to an AE, or death from any cause per RECIST, Version 1.1 by BICR was reported.
Time frame: Up to ~30 months
Overall Survival (OS)
OS, defined as the interval from the start of study treatment to death from any cause will be reported.
Time frame: Up to ~30 months
Number of Participants Who Experienced an Adverse Event (AE)
An AE was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE. The number of participants who experienced an AE was reported.
Time frame: Up to ~30 months
Number of Participants Who Discontinued Study Treatment Due to an AE
An AE was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE. The number of participants who discontinued study treatment due to an AE was reported.
Time frame: Up to ~11 months
Maximum Plasma Concentration (Cmax) of Zilovertamab Vedotin-Q1/3W Dosing Schedule
Cmax of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.
Time frame: Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days
Cmax of Total Antibody-Q1/3W Dosing Schedule
Cmax of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.
Time frame: Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days
Cmax of MMAE-Q1/3W Dosing Schedule
Cmax of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.
Time frame: Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days
Area Under the Plasma Concentration-time Curve (AUC) 0-504hrs of Zilovertamab Vedotin- Q1/3W Dosing Schedule
AUC0-504hrs of Zilovertamab Vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.
Time frame: Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days
AUC0-504hrs of Total Antibodies-Q1/3W Dosing Schedule
AUC0-504hrs of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.
Time frame: Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days
AUC0-504hrs of MMAE-Q1/3W Dosing Schedule
AUC0-504hrs of MMAE by blood collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.
Time frame: Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days
Cmax of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 1
Cmax of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
Time frame: Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days
Cmax of Total Antibody-Q2/3W Dosing Schedule: Day 1
Cmax of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
Time frame: Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days
Cmax of MMAE-Q2/3W Dosing Schedule: Day 1
Cmax of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
Time frame: Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days
Cmax of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 8
Cmax of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
Time frame: Day 8 [(predose; end of infusion (EOI)], Day 15 (168 hr), Cycle 2 Day 1 Predose; each cycle=21 days
Cmax of Total Antibody-Q2/3W Dosing Schedule: Day 8
Cmax of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
Time frame: Day 8 [(predose; end of infusion (EOI)], Day 15 (168 hr), Cycle 2 Day 1 Predose; each cycle=21 days
Cmax of MMAE-Q2/3W Dosing Schedule: Day 8
Cmax of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
Time frame: Day 8 [(predose; end of infusion (EOI)], Day 15 (168 hr), Cycle 2 Day 1 Predose; each cycle=21 days
AUC0-168hrs of Zilovertamab Vedotin -Q2/3W Dosing Schedule: Day 1
AUC0-168hrs of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
Time frame: Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days
AUC0-168hrs of Total Antibody-Q2/3W Dosing Schedule: Day 1
AUC0-168hrs of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that is not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
Time frame: Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days
AUC0-168 hr of MMAE-Q2/3W Dosing Schedule: Day 1
AUC0-168hrs of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
Time frame: Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days
AUC168-336hrs of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 8
AUC168-336 hrs of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
Time frame: Day 8 [(predose; end of infusion (EOI)], Day 15 (168hr), Cycle 2 Day 1 Predose; each cycle=21 days
AUC168-336 Hrs of Total Antibody-Q2/3W Dosing Schedule: Day 8
AUC168-336hrs of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to MMAE. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
Time frame: Day 8 [(predose; end of infusion (EOI)], Day 15 (168hr), Cycle 2 Day 1 Predose; each cycle=21 days
AUC168-336 hr of MMAE-Q2/3W Dosing Schedule: Day 8
AUC168-336 of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.
Time frame: Day 8 [(predose; end of infusion (EOI)], Day 15 (168hr), Cycle 2 Day 1 Predose; each cycle=21 days
| Milestone | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W |
|---|---|---|
| Started | 70 | 32 |
| Completed | 0 | 0 |
| Not completed | 70 | 32 |
| Withdrew: Study terminated | 7 | 8 |
| Withdrew: Death | 54 | 18 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 8 | 4 |
| Withdrew: Did not agree to follow-up | 0 | 1 |
The percentage of participants who achieved a Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: a ≥30% decrease in the sum of diameters \[SOD\] of target lesions) using per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 by BICR was reported.
| Percentage of Participants | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W |
|---|---|---|
| Objective Response Rate (ORR)- Blinded Independent Central Review (BICR) | 1.4 (0.0 to 7.7) | 0.0 (NA to NA) |
The percentage of participants who achieved a CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters \[SOD\] of target lesions) per RECIST, Version 1.1 by investigator was reported.
| Percentage of Participants | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W |
|---|---|---|
| ORR- Investigator Assessed | 1.4 (0.0 to 7.7) | 0.0 (NA to NA) |
TTR, defined as the time from the start of study treatment to the first documentation of objective tumor response per RECIST, Version 1.1 by BICR was reported.
| Months | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W |
|---|---|---|
| Time to Response (TTR)- BICR | 1.9 ± NA | — |
DOR, defined as the interval from the first documentation of objective tumor response to the earlier of the first documentation of disease progression or death from any cause per RECIST, Version 1.1 by BICR was reported.
| Months | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W |
|---|---|---|
| Duration of Response (DOR)- BICR | 1 (NA to NA) | — |
PFS, defined as the interval from the start of study treatment to the earlier of the first documentation of disease progression or death from any cause per RECIST, Version 1.1 by BICR was reported.
| Months | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W |
|---|---|---|
| Progression-free Survival (PFS)- BICR | 2.3 (2.0 to 4.1) | 1.9 (1.7 to 2.1) |
TTF, defined as the time from the start of study treatment to the earliest of the first documentation of disease progression, the permanent cessation of study drug due to an AE, or death from any cause per RECIST, Version 1.1 by BICR was reported.
| Months | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W |
|---|---|---|
| Time to Treatment Failure (TTF)- BICR | 2.2 (1.9 to 4.1) | 1.9 (1.7 to 2.1) |
OS, defined as the interval from the start of study treatment to death from any cause will be reported.
| Months | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W |
|---|---|---|
| Overall Survival (OS) | 8.3 (5.2 to 10.3) | 5.5 (4.4 to 11.0) |
An AE was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE. The number of participants who experienced an AE was reported.
| Participants | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W |
|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 70 | 32 |
An AE was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE. The number of participants who discontinued study treatment due to an AE was reported.
| Participants | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W |
|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE | 7 | 6 |
Cmax of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.
| μg/mL | Zilovertamab Vedotin Q1/3W |
|---|---|
| Maximum Plasma Concentration (Cmax) of Zilovertamab Vedotin-Q1/3W Dosing Schedule | 53.4 ± 20.5 |
Cmax of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.
| μg/mL | Zilovertamab Vedotin Q1/3W |
|---|---|
| Cmax of Total Antibody-Q1/3W Dosing Schedule | 51.2 ± 23.3 |
Cmax of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.
| μg/mL | Zilovertamab Vedotin Q1/3W |
|---|---|
| Cmax of MMAE-Q1/3W Dosing Schedule | 0.00393 ± 65.7 |
AUC0-504hrs of Zilovertamab Vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.
| hr*μg/mL | Zilovertamab Vedotin Q1/3W |
|---|---|
| Area Under the Plasma Concentration-time Curve (AUC) 0-504hrs of Zilovertamab Vedotin- Q1/3W Dosing Schedule | 4030 ± 27.3 |
AUC0-504hrs of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.
| hr*μg/mL | Zilovertamab Vedotin Q1/3W |
|---|---|
| AUC0-504hrs of Total Antibodies-Q1/3W Dosing Schedule | 6720 ± 28.6 |
AUC0-504hrs of MMAE by blood collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.
| hr*μg/mL | Zilovertamab Vedotin Q1/3W |
|---|---|
| AUC0-504hrs of MMAE-Q1/3W Dosing Schedule | 0.828 ± 58.1 |
Cmax of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
| μg/mL | Zilovertamab Vedotin Q2/3W |
|---|---|
| Cmax of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 1 | 28.6 ± 40.8 |
Cmax of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
| μg/mL | Zilovertamab Vedotin Q2/3W |
|---|---|
| Cmax of Total Antibody-Q2/3W Dosing Schedule: Day 1 | 26.2 ± 39.8 |
Cmax of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
| μg/mL | Zilovertamab Vedotin Q2/3W |
|---|---|
| Cmax of MMAE-Q2/3W Dosing Schedule: Day 1 | .00121 ± 332.3 |
Cmax of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
| μg/mL | Zilovertamab Vedotin Q2/3W |
|---|---|
| Cmax of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 8 | 35.0 ± 90.3 |
Cmax of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
| μg/mL | Zilovertamab Vedotin Q2/3W |
|---|---|
| Cmax of Total Antibody-Q2/3W Dosing Schedule: Day 8 | 39.1 ± 73.7 |
Cmax of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
| μg/mL | Zilovertamab Vedotin Q2/3W |
|---|---|
| Cmax of MMAE-Q2/3W Dosing Schedule: Day 8 | 0.00289 ± 90.9 |
AUC0-168hrs of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
| hr*μg/mL | Zilovertamab Vedotin Q2/3W |
|---|---|
| AUC0-168hrs of Zilovertamab Vedotin -Q2/3W Dosing Schedule: Day 1 | 2070 ± 26.1 |
AUC0-168hrs of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that is not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
| hr*μg/mL | Zilovertamab Vedotin Q2/3W |
|---|---|
| AUC0-168hrs of Total Antibody-Q2/3W Dosing Schedule: Day 1 | 2730 ± 25.0 |
AUC0-168hrs of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
| hr*μg/mL | Zilovertamab Vedotin Q2/3W |
|---|---|
| AUC0-168 hr of MMAE-Q2/3W Dosing Schedule: Day 1 | 0.202 ± 101.2 |
AUC168-336 hrs of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
| hr*μg/mL | Zilovertamab Vedotin Q2/3W |
|---|---|
| AUC168-336hrs of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 8 | 2900 ± 66.0 |
AUC168-336hrs of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to MMAE. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.
| hr*μg/mL | Zilovertamab Vedotin Q2/3W |
|---|---|
| AUC168-336 Hrs of Total Antibody-Q2/3W Dosing Schedule: Day 8 | 5890 ± 48.1 |
AUC168-336 of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.
| hr*μg/mL | Zilovertamab Vedotin Q2/3W |
|---|---|
| AUC168-336 hr of MMAE-Q2/3W Dosing Schedule: Day 8 | 0.596 ± 103.3 |
Collected over Up to 30 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zilovertamab Vedotin Q1/3W | 54/70 (77.1%) | 29/70 (41.4%) | 66/70 (94.3%) |
| Zilovertamab Vedotin Q2/3W | 18/32 (56.3%) | 16/32 (50%) | 30/32 (93.8%) |
| Event | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/70 | 1/32 |
| FatigueGeneral disorders | 0/70 | 2/32 |
| Neutrophil count decreasedInvestigations | 2/70 | 2/32 |
| PyrexiaGeneral disorders | 4/70 | 1/32 |
| PneumoniaInfections and infestations | 3/70 | 0/32 |
| Abdominal distensionGastrointestinal disorders | 0/70 | 1/32 |
| Small intestinal obstructionGastrointestinal disorders | 0/70 | 1/32 |
| VomitingGastrointestinal disorders | 1/70 | 1/32 |
| PainGeneral disorders | 0/70 | 1/32 |
| Sudden deathGeneral disorders | 0/70 | 1/32 |
| Event | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W |
|---|---|---|
| NauseaGastrointestinal disorders | 23/70 | 16/32 |
| FatigueGeneral disorders | 25/70 | 14/32 |
| Aspartate aminotransferase increasedInvestigations | 23/70 | 3/32 |
| DiarrhoeaGastrointestinal disorders | 21/70 | 6/32 |
| VomitingGastrointestinal disorders | 14/70 | 9/32 |
| Decreased appetiteMetabolism and nutrition disorders | 18/70 | 4/32 |
| Blood potassium decreasedInvestigations | 15/70 | 8/32 |
| Haemoglobin decreasedInvestigations | 15/70 | 8/32 |
| AlopeciaSkin and subcutaneous tissue disorders | 15/70 | 8/32 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 10/70 | 7/32 |
| Age, Continuous(Years) | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W | Total |
|---|---|---|---|
| Mean | 58.7 ± 11.79 | 62.7 ± 11.62 | 60.0 ± 11.82 |
| Sex: Female, Male(Participants) | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W | Total |
|---|---|---|---|
| Female | 64 | 24 | 88 |
| Male | 6 | 8 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 1 | 7 |
| Not Hispanic or Latino | 63 | 29 | 92 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | Zilovertamab Vedotin Q1/3W | Zilovertamab Vedotin Q2/3W | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 11 | 1 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 1 | 8 |
| White | 46 | 29 | 75 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 1 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pd
Data sharing details ↗ · engagezone.msd.com
Ran from Oct 2020 to primary completion in Jun 2023, 32 months.
Results were first posted in Aug 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zilovertamab vedotin
Triple Negative Breast Neoplasms →